ACRS

ACRS

Aclaris Therapeutics Inc. Common Stock

$1.535+0.000 (0.000%)

Preço em tempo real

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$1.535

Máximo

$1.535

Mínimo

$1.535

Volume

0.61M

Fundamentos da empresa

Estatísticas de negociação

Notícias relacionadas

GlobeNewswire

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today

Ver mais
Aclaris Therapeutics to Participate in Two June Healthcare Conferences
Analyst Upgrades

Wedbush Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $8

Wedbush analyst Martin Fan initiates coverage on Aclaris Therapeutics with a Outperform rating and announces Price Target of $8.

Ver mais
Wedbush Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $8
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $16

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aclaris Therapeutics with a Buy and lowers the price target from $20 to $16.

Ver mais
HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $16
GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ

Ver mais
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update